Pfizer Plans for First In-House RNAi Rx IND By 2011 as It Evaluates All Technologies

Having recently completed its acquisition of Coley Pharmaceutical, which specialized in modulating immune responses for therapeutic applications, Pfizer also sees the potential for combining RNAi with immune stimulation within a single drug.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register quickly here.